Bolus Calculation, Flexible Insulin Up Diabetes Control

This article originally appeared here.
Bolus Calculation, Flexible Insulin Up Diabetes Control
Bolus Calculation, Flexible Insulin Up Diabetes Control

(HealthDay News) – A structured course teaching the benefits of automated bolus calculator (ABC) use and flexible intensive insulin therapy (FIIT) improves metabolic control and satisfaction in patients with type 1 diabetes, according to a study published online Feb. 16 in Diabetes Care.

Signe Schmidt, MD, of Hvidovre University Hospital in Denmark, and associates evaluated a 16-week randomized clinical trial of 51 patients with type 1 diabetes to determine the effect of FIIT and ABC use. Eight participants were randomized to a control group; 21 to group teaching, which included FIIT and carbohydrate counting (CarbCount); and 22 to group teaching, which included FIIT and CarbCount using an ABC (CarbCountABC). The control group received FIIT education without carbohydrate counting.

The researchers found that, at 16 weeks, the within-group change in hemoglobin A1c (HbA1c) was −0.1%, −0.8%, and −0.7% in the control, CarbCount, and CarbCountABC groups, respectively. There was no significant difference between the change in the CarbCount and CarbCountABC groups. The relative change in HbA1c was −0.6% and −0.8% in the CarbCount and CarbCountABC groups, respectively, after adjusting for baseline HbA1c (P=0.082 and P=0.017, respectively). In all the study groups there was a significant improvement in treatment satisfaction, with a significantly greater improvement found in the CarbCountABC group.

"The principles of FIIT were successfully communicated to patients in a structured three-hour course," the authors write. "In addition, the study gives indications of increased treatment satisfaction and adherence with the concurrent use of an ABC."

Several authors disclosed financial ties to Roche, which provided glucose meters and bolus calculators. Medtronic provided glucose sensors and iPro2s. The study was partially funded by Novo Nordisk.

Abstract
Full Text (subscription or payment may be required)